When does cosentyx patent expire?

What is the patent expiration date for Cosentyx?

Cosentyx, also known as secukinumab, is a prescription medication used to treat a range of autoimmune conditions, including psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis. It's a biologic medication, and its patent is held by Novartis.

According to DrugPatentWatch.com[1], the US patent for secukinumab (marketed as Cosentyx) expired on October 8, 2028.

This means that once the patent expires, other pharmaceutical companies can apply to market their own versions of secukinumab, which could lead to increased competition and potentially lower prices for the medication.

Can biosimilars enter the market before the patent expires?

The US Biologics Price Competition and Innovation Act of 2009 allows for the approval of biosimilars, which are biologic medications that are highly similar to an approved referenced product.

Regulatory hurdles can delay the approval process for biosimilars. Currently, two biosimilars (Renflexis and Eylea) have been approved in the US, but none for secukinumab. It's unclear when, or if, a biosimilar for Cosentyx will be approved before the patent expires.

What happens when the patent expires?

Once the patent expires, generic or biosimilar versions of the medication may enter the market. This can lead to increased competition, potentially driving down prices and increasing patient access to affordable treatments.

On the other hand, patent expiration can also affect the revenue streams for pharmaceutical companies, which may lead to changes in their business strategies or investments in research and development.

Sources:

[1] DrugPatentWatch.com. (2023, February 22). Cosentyx: Secukinumab.